Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2003

View Archived Issues

Clinical benefits of efalizumab in plaque-type psoriasis

Good efficacy and safety profile reported for arzoxifene in hormone-sensitive breast cancer

New NK1 antagonists identified by Kyorin researchers

Novartis presents new PTP1B inhibitors in a recent patent

Spanish researchers prepare and test novel cannabinoid CB1 antagonists

Sumitomo claims TGF-beta antagonists with potential in fibrotic disorders

New EGFR inhibitors discovered at Boehringer Ingelheim

Ono claims novel prostanoid DP antagonists, their preparation and use

Pfizer scientists describe novel PPARgamma ligands and their use

Phase I trial begins for ChimeriVax-West Nile vaccine

Gene expression profiling for classifying pediatric ALL

Candidate gene for obesity located by international research team

Parkinson's disease: important genetic findings and RNAi-based drug development

Final results for phase II study of R-1549 in gastric cancer

Positive long-term data obtained for Aryplase

Rat study results for injectable sustained-release ZT-1 for Alzheimer's disease

Green light for phase I/II study of Enzo's gene vector for HIV

Guilford announces positive phase II results for Aquavan

Completion of first clinical study of Durect's postoperative pain depot product

Edaravone has beneficial effects in LPS-induced liver damage

Sativex marketing agreement extended to Canada

Shire and Noven work towards MethyPatch approval

Xcytrin evaluated in combination with Rituxan and Zevalin

Intranasal QR-435 prevents influenza infection in ferrets

Spotlight on systemic lupus erythematosus

Neuroprotective efficacy of neurosteroid in spinal cord ischemia

VP-025 prevents LPS-induced LTP impairment in rat brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...